| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143212 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months ago) | |
| US7119061 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months ago) | |
| US7115564 | ABBVIE | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(5 months ago) | |
| US6900175 | ABBVIE | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(4 years from now) | |
Dalvance is owned by Abbvie.
Dalvance contains Dalbavancin Hydrochloride.
Dalvance has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Dalvance are:
- US8143212
- US7119061
- US7115564
Dalvance was authorised for market use on 23 May, 2014.
Dalvance is available in powder;intravenous dosage forms.
Dalvance can be used as treatment of bacterial infections using a two-dose regimen of dalbavancin., treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose regimen of dalbavancin.
Drug patent challenges can be filed against Dalvance from 24 May, 2023.
The generics of Dalvance are possible to be released after 23 May, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2019 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2024 |
| New Dosing Schedule(D-154) | Jan 20, 2019 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 24 May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.; Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose re...
Dosage: POWDER;INTRAVENOUS
DALVANCE family patents
